Showing results (41-50 of 148) with videos related to

Sort By:
Pageof 15
Oncoimmunology|March 5, 2016
Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30Christian Kellner, Andreas Günther, Andreas Humpe, et al.
Critical Reviews in Immunology|June 19, 2014
Complement in antibody-based tumor therapyStefanie Derer, Frank J Beurskens, Thies Rosner, et al.
Frontiers in Immunology|September 2, 2022
Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumabNiklas Baumann, Christian Arndt, Judith Petersen, et al.
Cancer Immunology, Immunotherapy : CII|August 1, 2007
Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion proteinJulia Stieglmaier, Edwin Bremer, Christian Kellner, et al.
Cancer Research|January 23, 2014
Novel bispecific antibodies increase γδ T-cell cytotoxicity against pancreatic cancer cellsHans-Heinrich Oberg, Matthias Peipp, Christian Kellner, et al.
Cancer Letters|September 18, 2004
Nitric oxide is synthesized in acute leukemia cells after exposure to phenolic antioxidants and initially protects against mitochondrial membrane depolarizationChristian Kellner, Susan J Zunino
Hemasphere|March 4, 2024
Enhanced potency of immunotherapy against B-cell precursor acute lymphoblastic leukemia by combination of an Fc-engineered CD19 antibody and CD47 blockadeDenis M Schewe, Fotini Vogiatzi, Ira A Münnich, et al.
Frontiers in Immunology|December 23, 2024
Rituximab-IgG2 is a phagocytic enhancer in antibody-based immunotherapy of B-cell lymphoma by altering CD47 expressionOanh T P Nguyen, Sandra Lara, Giovanni Ferro, et al.
Mabs|February 5, 2014
HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate designBart E C G de Goeij, Matthias Peipp, Simone de Haij, et al.
Blood Advances|September 15, 2021
The selection of variable regions affects effector mechanisms of IgA antibodies against CD20Mitchell Evers, Thies Rösner, Anna Dünkel, et al.
Pageof 15